Evidence map›Paper›PMID 8195298›Full record

ArticleThe Journal of cell biology1994

Mapping the heparin-binding sites on type I collagen monomers and fibrils.

J D San Antonio, A D Lander, M J Karnovsky, H S Slayter

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of cell biology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 106 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Extracellular matrix components modulate different stages in βThe Journal of biological chemistry · 2019
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Preferential sites for intramolecular glucosepane cross-link formation in type I collagen: A thermodynamic study.Matrix biology : journal of the International Society for Matrix Biology · 2015
    Article
  15. Article
  16. Article
  17. Article
  18. Always cleave up your mess: targeting collagen degradation to treat tissue fibrosis.American journal of physiology. Lung cellular and molecular physiology · 2013
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

J D San AntonioDepartment of Pathology, Harvard Medical School, Boston, Massachusetts 02115.
A D Lander
M J Karnovsky
H S Slayter
Harvard University · US

Funding

TRANSCRIPTIONAL REGULATION OF VWF GENEP01HL033014 · NHLBI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ROSENBERG, ROBERT D · 1985 to 1994
–
ENDOTHELIAL INJURY AND REGENERATIONR01HL017747 · NHLBI · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI KARNOVSKY, MORRIS J · 1985 to 1989
–
ENDOTHELIAL INJURY AND REGENERATIONR37HL017747 · NHLBI · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI KARNOVSKY, MORRIS J · 1989 to 1998
–
NHLBI NIH HHS HL 17747NHLBI NIH HHS HL 33014
6 · The paper itself

Abstract

The glycosaminoglycan chains of cell surface heparan sulfate proteoglycans are believed to regulate cell adhesion, proliferation, and extracellular matrix assembly, through their interactions with heparin-binding proteins (for review see Ruoslahti, E. 1988. Annu. Rev. Cell Biol. 4:229-255; and Bernfield, M., R. Kokenyesi, M. Kato, M. T. Hinkes, J. Spring, R. L. Gallo, and E. J. Lose. 1992. Annu. Rev. Cell Biol. 8:365-393). Heparin-binding sites on many extracellular matrix proteins have been described; however, the heparin-binding site on type I collagen, a ubiquitous heparin-binding protein of the extracellular matrix, remains undescribed. Here we used heparin, a structural and functional analogue of heparan sulfate, as a probe to study the nature of the heparan sulfate proteoglycan-binding site on type I collagen. We used affinity coelectrophoresis to study the binding of heparin to various forms of type I collagen, and electron microscopy to visualize the site(s) of interaction of heparin with type I collagen monomers and fibrils. Using affinity coelectrophoresis it was found that heparin has similar affinities for both procollagen and collagen fibrils (Kd's approximately 60-80 nM), suggesting that functionally similar heparin-binding sites exist in type I collagen independent of its aggregation state. Complexes of heparin-albumin-gold particles and procollagen were visualized by rotary shadowing and electron microscopy, and a preferred site of heparin binding was observed near the NH2 terminus of procollagen. Native or reconstituted type I collagen fibrils showed one region of significant heparin-gold binding within each 67-nm period, present near the division between the overlap and gap zones, within the "a" bands region. According to an accepted model of collagen fibril structure, our data are consistent with the presence of a single preferred heparin-binding site near the NH2 terminus of the collagen monomer. Correlating these data with known type I collagen sequences, we suggest that the heparin-binding site in type I collagen may consist of a highly basic triple helical domain, including several amino acids known sometimes to function as disaccharide acceptor sites. We propose that the heparin-binding site of type I collagen may play a key role in cell adhesion and migration within connective tissues, or in the cell-directed assembly or restructuring of the collagenous extracellular matrix.

Indexed as

Amino Acid SequenceAnimalsBinding SitesChick EmbryoChondroitinases and Chondroitin LyasesCollagenHeparinMicroscopy, ElectronMolecular Sequence DataProcollagenRatsChondroitinases and Chondroitin LyasesCollagenHeparinProcollagen

Identifiers

PMID8195298
PMCPMC2120046
OpenAlexW2113288839

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.